Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Conditions
- Interventions
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 147
- Registration Number
- NCT03644186
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Berard, Lyon, France
🇮🇹Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT03633331
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Cancer Center, Post Falls, Idaho, United States
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03628066
- Locations
- 🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇺🇸Saddleback Memorial Medical Center, Laguna Hills, California, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 366
- Registration Number
- NCT03609047
- Locations
- 🇧🇪
Heilig Hartziekenhuis Lier, Lier, Belgium
🇵🇱Medical University Of Gdansk, Gdansk, Poland
🇵🇹Centro Hospitalar do Porto-- Hospital de Santo Antonio, Porto, Portugal
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-03-27
- Target Recruit Count
- 33
- Registration Number
- NCT03573648
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study of ZN-c5 in Subjects With Breast Cancer
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Zeno Alpha Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03560531
- Locations
- 🇨🇿
Site 30, Praha 5, Czechia
🇺🇸Site 3, Tucson, Arizona, United States
🇺🇸Site 5, Los Angeles, California, United States
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 17
- Registration Number
- NCT03535506
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Medstar Washington Hospital Center, Washington, District of Columbia, United States
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 55
- Registration Number
- NCT03530696
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸JPS Health Network, Fort Worth, Texas, United States
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT03526250
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Kathryn Gold
- Target Recruit Count
- 24
- Registration Number
- NCT03498378
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.